Bharat Biotech Enrols Over 25,000 Volunteers For Covaxin Phase 3 Trial | Read
PUBLISHED ON: January 7, 2021 | Duration: 2 min, 22 sec
Bharat Biotech has enrolled 25,800 volunteers for phase 3 clinical trials of its COVID-19 vaccine, the company said today. The maker of Covaxin is one of the two firms cleared by the government to deploy their product for mass inoculation in the country. The other is Oxford-AstraZeneca's Covishield manufactured by the Serum Institute of India.